This strategy may be extremely valuable in patients with advanced localized or metastatic bladder cancer which is characterized by high numbers of circulating MDSCs, frequent up-regulation of PD-L1 expression and significant infiltration of tumor tissue with immunosuppressive cell subsets. The gene discussed is CD274; the disease is neoplasm.